Role of farnesyltransferase inhibitors in hematologic malignancies.

Abstract excerpt

The treatment of hematologic malignancies has progressed in the last few years. Identification of new pathways and target molecules in leukemia has ushered in a promising new era of therapy. Ras mutations have recently been implicated in the pathogenesis of acute leukemia, and inhibition of Ras signaling through the use of farnesyltransferase inhibitors (FTIs) has shown promise in early trials in acute myeloid...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Enzyme Inhibitors
• Share to Farnesyltranstransferase
• Share to Hematologic Neoplasms